BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//European Brain Council (EBC) - ECPv6.15.19//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:European Brain Council (EBC)
X-ORIGINAL-URL:https://www.braincouncil.eu
X-WR-CALDESC:Events for European Brain Council (EBC)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180425
DTEND;VALUE=DATE:20180426
DTSTAMP:20260415T202727
CREATED:20200311T101837Z
LAST-MODIFIED:20200311T101837Z
UID:20235-1524614400-1524700799@www.braincouncil.eu
SUMMARY:National Workshop on Off-label Use of Medicines: Declaración sobre buenas prácticas del uso fuera de guía de medicamentos en España - 25th April 2018
DESCRIPTION:The Spanish Brain Council (SBC)\, in cooperation with the European Brain Council (EBC)\, will hold the workshop “Declaración sobre buenas prácticas del uso fuera de guía de medicamentos en España” on 25th April in Madrid. \nOrganized against the backdrop of the Good Off-Label Use Practice (GOLUP) campaign\, this workshop aims to raise awareness of the 5 principles laid down in the GOLUP-declaration and facilitate an exchange of views amongst policy-makers and healthcare stakeholder on issues related to off-label use in Spain. The forthcoming event in Madrid is the second national workshop organized in the context of EBC’s advocacy work on off-label use of medicines. \nThe European Commission’s “Study on off-label use of medicinal products in the European Union” released in February 2017 indicated that the use of medicines off-label is a widespread phenomenon across Europe. Off-label use of medicines\, i.e. the practice of using a medicine outside its authorised indication\, for another patient group or in a different dose\, can offer solutions in areas of unmet medical needs but also presents challenges related to therapeutic innovation\, patient safety and professional liability. \nIn view of this and in order to provide further clarify on when medicinal products can be safely prescribed off-label\, EBC as well as 12 other organizations have endorsed the GOLUP-declaration. This document calls on regulators to adopt guidelines on the practice of off-label use and includes 5 criteria aimed at enhancing patient safety. \nThe forthcoming workshop in Madrid will bring together a wide range of brain researchers\, scientists\, policy-makers and healthcare professionals in order to address some of the challenges presented by off-label use in Spain. Speakers include: \n\nFrédéric Destrebecq – European Brain Council / Consejo Europeo del Cerebro\nCesar Hernandez Garcia – Spanish Agency of Medicines and Medical Devices / Agencia Española de Medicamentos y Productos Sanitarios\nAlba Ancochea Díaz – Spanish Federation of Rare Diseases / Federación Española de Enfermedades Raras\nJosé Ramón Ara Callizo – Spanish Society of Neurology / Sociedad Española de Neurología\nCelso Arango López – European College of Neuropsychopharmacology\nJavier Pardo Moreno – Rey Juan Carlos Hospital\nMarina Díaz Marsá – Foundation for Neurodegenerative Diseases Investigation\nRepresentative from Farmaindustria (TBC)\nRepresentative from the Ministry of Health (TBC)\n\nShould you be interested in attending this workshop\, please do not hesitate to reach out to us (policy@braincouncil.eu or +32 (0)2 513 27 57).
URL:https://www.braincouncil.eu/event/national-workshop-on-off-label-use-of-medicines-declaracion-sobre-buenas-practicas-del-uso-fuera-de-guia-de-medicamentos-en-espana-25th-april-2018/
END:VEVENT
END:VCALENDAR